Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis

@article{Allen2005LowDD,
  title={Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis},
  author={Stephen C. Allen and Satru Raut and Janet Woollard and Michael Vassallo},
  journal={Palliative Medicine},
  year={2005},
  volume={19},
  pages={128 - 130}
}
There is very little evidence regarding the safety and efficacy of opioids for the control of dyspnoea in the terminal stages of idiopathic pulmonary fibrosis (IPF). We conducted an open case series study of 11 elderly opioid-naive patients referred for management of severe breathlessness before and after their first injection of 2.5 mg diamorphine subcutaneously. Subjective breathlessness, measured by a 100 mm visual analogue scale, fell by a mean of 47 mm in the first 15 min (PB 0.0001) and… Expand
Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease – a randomised placebo-controlled trial
TLDR
Oral morphine did not induce respiratory depression, but was related to an increased risk of constipation, nausea and confusion, and oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test. Expand
Low-Dose Morphine for Dyspnea in Terminally Ill Patients with Idiopathic Interstitial Pneumonias.
TLDR
Dyspnea severity measured using numerical rating scale (NRS) and respiratory rate (RR) before and two and four hours after morphine initiation and the effectiveness and safety of continuous subcutaneous morphine for dyspnea in terminally ill IIP patients are examined. Expand
Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis
TLDR
There is no evidence of significant or clinically relevant respiratory adverse effects of opioids for chronic breathlessness and Heterogeneity of design and study population, and low study quality are limitations. Expand
Opioid Use in End-of-Life Care in Patients With Interstitial Pneumonia Associated With Respiratory Worsening
TLDR
The treatment outcome of patients with severe interstitial pneumonia who received opioids during end-of-life care was investigated, and dyspnea should be monitored and recorded in routine clinical practice, at least after hospitalization. Expand
Chronic breathlessness in patients with idiopathic pulmonary fibrosis: a major challenge for caregivers
TLDR
The evidence for efficacy of a number of therapeutic interventions currently at disposal for the management of breathlessness in IPF, which aim to reduce respiratory neural drive, reduce worsening of mechanical load, and alter central perception are examined. Expand
Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response.
TLDR
A moderate morphine dose produced substantial relief of laboratory dyspnea, with a smaller reduction of ventilation, and this laboratory model of air hunger established a highly significant treatment effect consistent in magnitude with clinical studies of opioids. Expand
Pharmacological management of dyspnoea
TLDR
Low-dose regular opioids, especially sustained-release preparations, have a key role in the pharmacological management of dyspnoea when titrated for effect, and may be used regularly across a range of underlying pathophysiologies. Expand
Opioids prescription for symptoms relief and the impact on respiratory function: updated evidence
TLDR
Whether or not the situation of an advanced-stage patient under palliative care and the use of opioids are risk factors for respiratory depression and their safe use in end-stage patients is determined. Expand
Inspiratory neural drive and dyspnea in interstitial lung disease: Effect of inhaled fentanyl
TLDR
IND rose sharply during constant work rate exercise in association with dyspnea intensity in mild to moderate ILD but was not different after nebulized fentanyl compared with placebo. Expand
Pathophysiologies of dyspnea explained: why might opioids relieve dyspnea and not hasten death?
TLDR
Palliative care clinicians have advocated for the use of opioids in the treatment of patients with dyspnea that is resistant to disease modification and possible effects of opioids on this pathophysiology are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Low-dose nebulized morphine does not improve exercise in interstitial lung disease.
TLDR
The administration of low-dose nebulized morphine to subjects with ILD neither relieves their dyspnea during exercise nor improves their maximal exercise performance. Expand
Opioids for dyspnoea
TLDR
A meta-analysis of randomised controlled trials of opioids as treatment for dysPNoea shows that opioids do reduce dyspnoea in a variety of settings, including chronic obstructive pulmonary disease (COPD) and cancer. Expand
Opioids for the palliation of breathlessness in terminal illness.
TLDR
There is evidence to support the use of oral or parenteral opioids to palliate breathlessness although numbers of patients involved in the studies were small and no evidence was found to supportThe use of nebulised opioids. Expand
The experience of breathlessness in lung cancer.
Breathlessness is a common problem in advanced cancer ranked amongst the 10 most common symptoms in patients admitted to palliative care units. Alongside coughing, it is the most commonly reportedExpand
Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea
TLDR
Sustained release, oral morphine at low dosage provides significant symptomatic improvement in refractory dyspnoea in the community setting. Expand
Dyspnea assessment and management in hospice patients with pulmonary disorders
TLDR
Methods of assessing dyspnea and interventions used to manage Dyspnea in 72 hospice patients with end-stage lung disease or lung cancer are described and significant decline in functional and cognitive status is shown, but no significant changes in dyspna severity and pain. Expand
A systematic review of the use of opioids in the management of dyspnoea
TLDR
This review supports the continued use of oral and parenteral opioids to treat dyspnoea in patients with advanced disease and concludes whether nebulised opioids are effective, but the results from included studies that did not contribute to the meta-analysis suggest that they are no better than neBulised normal saline. Expand
Dyspnea and decreased variability of breathing in patients with restrictive lung disease.
TLDR
Patients with restrictive lung disease adopt a tightly constrained breathing pattern, probably as a strategy for avoiding dyspnea, and the relationship was parabolic. Expand
A clinical study of idiopathic pulmonary fibrosis based on autopsy studies in elderly patients.
TLDR
The poor outcome in IPF in elderly patients was characterized by more severe dyspnea, advanced age and co-morbidity. Expand
Management of dyspnea in advanced cancer patients
TLDR
While benzodiazepines are frequently used in patients with dyspnea, these drugs were ineffective in four out of five randomized controlled trials and currently available evidence does not support the clinical use of nebulized opioids. Expand
...
1
2
...